Johnson & Johnson Highlights Growth Strategy

Johnson & Johnson will review growth strategies for its Pharmaceuticals business and address therapeutic area strategy, advancing key compounds in its pipeline, and leveraging global market strategies to grow market share and expand geographic presence. J&J plans to continue to address and build on five therapeutic areas: neuroscience, cardiovascular and metabolism, immunology, oncology and infectious diseases/vaccines.

“Our people focus every day on addressing the world’s major unmet medical needs with superior science,” said vice chairman, executive committee, Sheri McCoy. “Since our last Pharmaceuticals Business Review with analysts in 2009, we have built a highly productive pharmaceuticals pipeline, with six key new products launching and another two pending regulatory review, some in multiple geographies. Our disciplined approach to R&D, rigorous investment prioritization, and internal and external sources of innovation, have enabled us to be well-positioned for long-term growth.Our revitalized portfolio and launch capabilities have led to market leadership in key categories.”

The company’s four strategies to grow its pharmaceuticals business include:

• focusing on differentiated medicines by expanding in immunology, oncology and vaccines,
• prioritizing investments in internal R&D, strategic licensing, partnerships and select acquisitions to build a robust pipeline for the long-term,
• strengthening its geographic presence and increase investments in emerging markets, as well as remain focused on key developed markets, particularly Japan,
• investing in talent and organizational capabilities locally, regionally and globally, building R&D capabilities in new technology areas and emerging markets.

J&J’s pharmaceuticals business invested approximately $4.4 billion in R&D programs last year. Paul Stoffels, M.D., worldwide chairman, Pharmaceuticals, said, “Innovation and sustained R&D productivity are key to our long-term future. The future drivers for success in pharmaceuticals will depend on matching the medical need with the best science and operational excellence. Our development programs incorporate an outcomes-based approach, embedding customer, physician, and patient insights, while our broad-based expertise and global development operations allow us to deliver competitive products globally, with enhanced productivity and accelerated timelines.”